A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence 'VANISH-2'
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2015
At a glance
- Drugs Polidocanol (Primary)
- Indications Varicose veins
- Focus Registrational; Therapeutic Use
- Acronyms VANISH-2
- Sponsors BTG; BTG International
- 01 Apr 2014 The drug dosage has been changed as as reported by ClinicalTrials.gov record.
- 04 Mar 2014 New trial record
- 21 Feb 2014 One-year data from the VANISH-2 trial presented at the 26th Annual Meeting of the American Venous Forum, according to a BTG media release.